Can domperidone be used safely in a 12‑year‑old child, and what is the recommended dosage and monitoring?

Domperidone Use in 12-Year-Olds

Domperidone can be used in adolescents aged 12–17 years for nausea and vomiting, but only for short-term treatment (≤7 days) at restricted doses (≤30 mg/day), with mandatory ECG monitoring for QT prolongation. 1, 2

Regulatory Status and Approved Indications

• Domperidone is not FDA-approved for any indication in humans in the United States 3
• In Europe and other jurisdictions where it is available, current use is restricted to relief of nausea and vomiting in children older than 12 years for a short period of time 4
• The European Medicines Agency imposed strict usage restrictions in 2014 limiting age (≤60 years), daily dose (≤30 mg/day), and duration (≤7 days) due to increased sudden death risk 5

Dosing for 12-Year-Olds

• Recommended dose: 10–20 mg three times daily 2
• Maximum daily dose: 30 mg/day (doses >10 mg three times daily are discouraged due to increased QT-prolongation risk) 2, 5
• Maximum treatment duration: 7 days 5
• Administer before meals 2

Cardiac Safety and Monitoring Requirements

Baseline Assessment:

• Obtain ECG to assess QTc interval before initiating therapy 6, 2
• Measure serum potassium and magnesium levels 6, 2
• Screen for cardiac history including arrhythmias, structural heart disease, or family history of sudden cardiac death 6

Ongoing Monitoring:

• Perform periodic ECG monitoring throughout therapy to assess for QTc prolongation 6, 2
• Monitor serum potassium and magnesium levels periodically 6, 2
• Discontinue domperidone if QTc interval exceeds 500 ms (confirmed by repeat ECG) 6

Contraindications in Adolescents

Absolute contraindications:

• Baseline QTc interval >450 ms that does not correct with medical management 7
• Patient or family history of cardiac arrhythmias 7
• Severe cardiac disease 7
• Suspected or confirmed gastrointestinal blockage (domperidone is a prokinetic drug) 3
• Allergy to domperidone or metronidazole 7

Drug Interactions Requiring Caution

• Antiarrhythmics (amiodarone, sotalol, quinidine): increased risk of QT prolongation 6
• Fluoroquinolones: risk of prolonged QT interval 6
• Macrolides (erythromycin): significant inhibition of domperidone metabolism resulting in multi-fold increase in drug exposure 6, 3
• Azole antifungals (ketoconazole): increased domperidone exposure 6
• Clofazimine: risk of prolonged QT interval 6

Clinical Context for Use

Appropriate indications in 12-year-olds:

• Nausea associated with migraine (though oral administration is unlikely to prevent vomiting) 1
• Short-term relief of nausea and vomiting from other causes 4

Off-label use (common but not evidence-based):

• Gastroesophageal reflux disease 4
• Dyspepsia 4
• Gastroparesis 4

Evidence Limitations

• A 2019 randomized controlled trial in children aged 6 months to 12 years with acute gastroenteritis found no significant difference between low-dose domperidone (0.25 mg/kg three times daily) and placebo in reducing vomiting or nausea episodes 8
• Most pediatric studies have limited sample sizes and controversial efficacy data 4
• Pathological QTc intervals have been documented in a small number of infants receiving domperidone, supporting the possibility of QT prolongation risk 9

Critical Safety Pitfalls

• Do not exceed 7 days of treatment without reassessing risk-benefit ratio 5
• Do not use doses >30 mg/day due to increased cardiac risk 2, 5
• Do not prescribe without baseline ECG to identify pre-existing QT prolongation 6, 2
• Do not combine with other QT-prolonging medications without careful monitoring 6
• Do not use if domperidone is unavailable through proper regulatory channels in the United States (requires FDA expanded-access IND application) 2

Neurological Safety Advantage

• Unlike metoclopramide, domperidone has minimal central nervous system side effects because it does not readily cross the blood-brain barrier 3, 2
• No risk of extrapyramidal symptoms or tardive dyskinesia that are associated with metoclopramide 2